RESUMEN
BACKGROUND: The patent ductus arteriosus (PDA) represents one of the most prevalent diseases in hospitals which treat congenital heart diseases (CHD). Currently, in groups of more than 1 year of age percutaneous closure it is the standard therapy. The aim of this paper is to determine the frequency, characteristics and treatment of PCA in congenital heart disease service at the a Cardiology Hospital in Mexico. METHODS: In clinical CHD our hospital, a descriptive study of 2010-2015 of patients who were treated with percutaneous closure PCA and surgery was performed. They were divided into the following ages: infant, preschool, children, adolescents and adults. The absolute frequencies were recorded. RESULTS: 187 patients of preschool and school which accounted for 60% of the total sample were obtained. Percutaneous closure catheterization was performed in 90%; 2% of complications were recorded. CONCLUSIONS: In this clinic, the PCA is treated mostly by interventional catheterization in most stages of the human being with minimal complications.
Introducción: la persistencia del conducto arterioso (PCA) representa una de las enfermedades con mayor prevalencia en los hospitales que atienden cardiopatías congénitas (CC). En la actualidad en pacientes mayores de un año de edad el cierre percutáneo es la terapéutica estándar. El objetivo de este trabajo fue conocer la frecuencia, características y tratamiento de PCA en el servicio de Cardiopatías Congénitas en el Hospital de Cardiología del Centro Médico Nacional Siglo XXI. Métodos: en el servicio de Cardiopatías Congénitas del Hospital de Cardiología del CMN SXXI se realizó un estudio descriptivo de 2010 a 2015 de los enfermos que fueron tratados con cierre percutáneo y cirugía de PCA. Se dividieron en las siguientes edades: lactantes, preescolares, escolares, adolescentes y adultos. Se registraron las frecuencias absolutas. Resultados: se seleccionaron 187 pacientes, de los cuales los preescolares y escolares representaron el 60% del total de la muestra. El cierre percutáneo por cateterismo intervencionsta se realizó en 90%; se registró un 2% de complicaciones. Conclusiones: en esta clínica de cardiopatías congénitas, la PCA es tratada por cateterismo intervencionista en la mayoría de las etapas del ser humano, lo que ha registrado mínimas complicaciones.
Asunto(s)
Conducto Arterioso Permeable/cirugía , Adolescente , Adulto , Instituciones Cardiológicas , Cateterismo Cardíaco , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , México , Persona de Mediana Edad , Procedimientos Quirúrgicos Mínimamente Invasivos , Resultado del Tratamiento , Adulto JovenRESUMEN
Determination of anti-citrullinated peptide antibodies (ACPA) plays a relevant role in the diagnosis of rheumatoid arthritis (RA). To date, it is still unclear if the use of several tests for these autoantibodies in the same patient offers additional value as compared to performing only one test. Therefore, we evaluated the performance of using two assays for ACPA: second-generation anti-citrullinated cyclic peptides antibodies (anti-CCP2) and anti-mutated citrullinated vimentin (anti-MCV) antibodies for the diagnosis of RA. We compared three groups: RA (n = 142), chronic inflammatory disease (CIRD, n = 86), and clinically healthy subjects (CHS, n = 56) to evaluate sensitivity, specificity, predictive values, and likelihood ratios (LR) of these two assays for the presence of RA. A lower frequency of positivity for anti-CCP2 was found in RA (66.2%) as compared with anti-MCV (81.0%). When comparing RA versus other CIRD, sensitivity increased when both assays were performed. This strategy of testing both assays had high specificity and LR+. We conclude that adding the assay of anti-MCV antibodies to the determination of anti-CCP2 increases the sensitivity for detecting seropositive RA. Therefore, we propose the use of both assays in the initial screening of RA in longitudinal studies, including early onset of undifferentiated arthritis.